跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
TGA
/
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial
Approved
STANDARD
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial
Eugia Pharma (Australia) Pty Ltd
🇦🇺 Therapeutic Goods Administration
Approval Date
Dec 9, 2025
Approval ID
2b163544e63cf5b6
Company
Eugia Pharma (Australia) Pty Ltd
Type
Standard
Approval Details
Approval Id
2b163544e63cf5b6
Product Name
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial
Artg Id
439211
Artg Name
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial
Sponsor
Eugia Pharma (Australia) Pty Ltd
Company Detail Path
/organization/eugia-pharma-australia-pty-ltd
Artg Date
2025-03-17
Registration Type
Medicine
Therapeutic Good Type
Medicine
Licence Status
A
Licence Category
RE
Approved
Quick Info
Agency
TGA
Country
🇦🇺
Approval Date
Dec 9, 2025
Approval ID
2b163544e63cf5b6
Type
Standard
Back to TGA Approvals
IRINOTECAN EPSL irinotecan hydrochloride trihydrate 40 mg/2 mL concentrated injection vial - TGA Drug Approval Details